Novonorm

Basic NovoNorm information

• INN (international nonproprietary name): Repaglinide.
• Brand names available in the United Kingdom: NovoNorm and generic repaglinide.
• ATC code: A10BX02.
• Forms & Dosages: Tablets 0.5 mg, 1 mg and 2 mg.
• Manufacturers in the United Kingdom: Novo Nordisk (NovoNorm) and generic manufacturers.
• Registration status in the United Kingdom: Prescription-only medicine (POM)
• OTC / Rx classification: Prescription only (Rx)

Legal status and availability in the UK

Repaglinide (NovoNorm) is a prescription-only medicine (POM) in the UK.

In our online pharmacy, NovoNorm is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Patients often want to know how repaglinide performs in routine NHS practice compared with other options.

In the UK, repaglinide is used selectively rather than widely as a second‑ or third‑line agent for type 2 diabetes.

Common indications include metformin intolerance or contraindication and management of post‑meal hyperglycaemia.

In UK practice repaglinide, commonly prescribed as NovoNorm or generic repaglinide, reliably lowers prandial glucose when taken 0–30 minutes before meals.

Treatment usually starts at 0.5 mg per main meal (1 mg when transferring from another oral antidiabetic), with titration at 1–2 week intervals.

Meal‑time flexibility is a frequent patient benefit, which helps shift workers and erratic eaters.

The main concerns are hypoglycaemia and the burden of remembering doses at every main meal.

Primary‑care safety monitoring usually includes periodic HbA1c checks plus renal and liver function tests and targeted hypoglycaemia counselling.

Indications and expanded uses

Patients commonly ask what repaglinide is licensed for and when clinicians consider off‑label use.

• Licensed use: Indicated for type 2 diabetes mellitus as an adjunct to diet and exercise; tablets available in 0.5 mg, 1 mg and 2 mg strengths.
• Off‑label examples: Short‑term bridging in selected specialist clinics while titrating other agents; cautious combination with basal insulin under specialist supervision (rare).
• Contraindications: Type 1 diabetes, diabetic ketoacidosis, known hypersensitivity to repaglinide or excipients, and concurrent gemfibrozil use.

Initial adult regimen is 0.5–1 mg with meals, titrated up to 4 mg per dose and 16 mg daily maximum.

Repaglinide is prescription only and is most often selected to manage post‑meal hyperglycaemia, particularly in people with irregular meal patterns or metformin intolerance.

Composition and brand landscape

Patients want clarity on what is in the tablets and which brands they may receive from the pharmacy.

Active ingredient: repaglinide (INN), classified under ATC A10BX02 as a meglitinide or glinide oral antidiabetic.

Dosage strengths in the UK follow the standard 0.5 mg, 1 mg and 2 mg tablet presentations.

Repaglinide is a prescription-only medicine and is supplied with a patient information leaflet.

Contraindications and special precautions

People often worry about who should not take repaglinide and when extra caution is needed.

Absolute contraindications include type 1 diabetes, diabetic ketoacidosis, known hypersensitivity and concomitant gemfibrozil use due to severe hypoglycaemia risk.

Precautions include elderly patients, anyone with hepatic or renal impairment, undernourished individuals, heavy alcohol use and those with irregular food intake because these increase hypoglycaemia risk.

The SPC and MHRA advise avoiding repaglinide in severe hepatic impairment and starting at the lowest dose with careful monitoring in renal impairment.

Driving and work‑safety counselling is routine in NHS reviews and patients should be warned about hypoglycaemia signs such as sweating, tremor and confusion.

Pregnancy and breastfeeding data are limited and specialists usually advise against use without expert input.

High‑risk checks and monitoring schedule:

• Baseline and periodic HbA1c.
• Baseline and repeat liver function tests, especially in suspected hepatic impairment.
• Renal function monitoring and dose adjustment as required.

Common adverse effects include hypoglycaemia, abdominal pain and diarrhoea.

Storage and missed‑dose instructions reinforce the need to skip the dose if a meal is skipped and not to double up on the next occasion.

Dosage guidelines

Patients frequently ask exactly when to take tablets and how dosing is adjusted in practice.

Standard NHS‑aligned adult dosing is to take repaglinide orally 0–30 minutes before each main meal.

Initial dosing commonly starts at 0.5 mg per meal (1 mg when transferring from another oral antidiabetic), with titration at 1–2 week intervals as needed.

Maximum single dose is 4 mg and maximum total daily dose is 16 mg.

Missed meals: skip the missed dose and resume at the next meal; do not double doses.

NHS workflow: GP usually starts treatment and pharmacists reinforce timing, hypoglycaemia rescue and record counselling in pharmacy notes.

Interactions overview

People ask which medicines and foods increase danger when taking repaglinide.

Gemfibrozil is a well documented contraindication because it markedly raises repaglinide plasma levels and can cause severe hypoglycaemia.

CYP3A4 and CYP2C8 inhibitors or strong modulators can alter metabolism and require caution; examples include some azole antifungals and certain macrolide antibiotics.

Conversely, enzyme inducers may reduce repaglinide efficacy and require dose review.

Alcohol increases hypoglycaemia risk and patients are advised to minimise intake and monitor glucose closely when drinking.

Pharmacists routinely check interaction flags at dispensing and advise on hypoglycaemia signs and rescue measures.

Comparable medicines and prescribing preferences

Patients and prescribers often ask what alternatives exist and why one agent might be chosen over another.

NHS formularies keep metformin as first‑line and select alternatives based on comorbidities and individual risk.

Repaglinide is compared with sulfonylureas such as glimepiride and gliclazide, other meglitinides like nateglinide, DPP‑4 inhibitors and SGLT2 inhibitors.

DPP‑4 and SGLT2 classes are often preferred when hypoglycaemia risk or weight profile is a priority.

Repaglinide is favoured when meal irregularity, rapid prandial coverage or metformin intolerance are deciding factors.

Pros and cons:

• Efficacy for postprandial spikes: Repaglinide has rapid onset suited to mealtime coverage.
• Hypoglycaemia risk: Present; generally lower duration than some sulfonylureas but higher than DPP‑4s or SGLT2s.
• Weight effect: May be weight‑neutral or cause modest weight gain compared with SGLT2s which can support weight loss.
• Monitoring needs: Regular HbA1c and periodic LFTs/renal checks as per NHS guidance.

Frequently asked questions

How should I take repaglinide?

Take 0–30 minutes before each main meal using the prescribed tablet strength (0.5 mg, 1 mg or 2 mg).

If you skip a meal, skip the dose for that meal and resume with the next meal; do not double up.

What are the main side effects?

The most common is hypoglycaemia, with symptoms such as sweating, tremor and confusion.

Other common side effects include abdominal pain and diarrhoea.

Can I drink alcohol?

Alcohol increases the risk of hypoglycaemia and should be minimised, with extra glucose monitoring when drinking.

Is repaglinide available on the NHS?

Yes, repaglinide is prescription‑only and can be prescribed on the NHS.

Guidelines for proper use

Patients often ask what to expect from pharmacy counselling when collecting NovoNorm or repaglinide.

Pharmacist counselling checklist:

• Confirm indication and dosing schedule (take 0–30 minutes before meals).
• Review recent HbA1c target and readings.
• Ask about liver or renal disease, alcohol use and other medicines, with an explicit check for gemfibrozil.
• Explain hypoglycaemia recognition and rescue: oral glucose tablets, sugary drinks and glucagon if prescribed.
• Advise on storage: keep in original packaging and avoid extremes of temperature.
• Provide missed‑dose rules and emphasise not to double doses.
• Document counselling in pharmacy records and recommend GP review if hypoglycaemia is recurrent.

NHS support and referral points:

Signpost Diabetes UK for peer support and DESMOND structured education for newly diagnosed patients or those changing therapy.

Use EPS flags to prevent co‑prescription with gemfibrozil and to prompt warnings for elderly patients and hepatic impairment.

Delivery across the United Kingdom